These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1095 related articles for article (PubMed ID: 34597941)

  • 41. Post-vaccination antibody evaluation for nosocomial SARS-CoV-2 delta variant breakthrough infection.
    Goto T; Tani N; Ikematsu H; Gondo K; Oishi R; Minami J; Onozawa K; Kuwano H; Akashi K; Shimono N; Chong Y
    PLoS One; 2022; 17(7):e0272056. PubMed ID: 35877668
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer.
    Goshen-Lago T; Waldhorn I; Holland R; Szwarcwort-Cohen M; Reiner-Benaim A; Shachor-Meyouhas Y; Hussein K; Fahoum L; Baruch M; Peer A; Reiter Y; Almog R; Halberthal M; Ben-Aharon I
    JAMA Oncol; 2021 Oct; 7(10):1507-1513. PubMed ID: 34236381
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunogenicity of BNT162b2 Vaccination against SARS-CoV-2 Omicron Variant and Attitudes toward a COVID-19 Booster Dose among Healthy Thai Adolescents.
    Assavavongwaikit P; Chantasrisawad N; Himananto O; Phasomsap C; Klawaja P; Cartledge S; Nadsasarn R; Jupimai T; Kawichai S; Anugulruengkitt S; Puthanakit T; On Behalf Of The Study Team
    Vaccines (Basel); 2022 Jul; 10(7):. PubMed ID: 35891264
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunogenicity, safety and clinical outcomes of the SARS-CoV-2 BNT162b2 vaccine in adolescents with type 1 diabetes.
    Emeksiz HC; Hepokur MN; Şahin SE; Şirvan BN; Çiçek B; Önder A; Yıldız M; Aksakal DK; Bideci A; Ovalı HF; İşman F
    Front Pediatr; 2023; 11():1191706. PubMed ID: 37435175
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Decline of antibody titres 3 months after two doses of BNT162b2 in non-immunocompromised adults.
    Erice A; Varillas-Delgado D; Caballero C
    Clin Microbiol Infect; 2022 Jan; 28(1):139.e1-139.e4. PubMed ID: 34508885
    [TBL] [Abstract][Full Text] [Related]  

  • 46. SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients - A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel Disease.
    Wagner A; Garner-Spitzer E; Schötta AM; Orola M; Wessely A; Zwazl I; Ohradanova-Repic A; Weseslindtner L; Tajti G; Gebetsberger L; Kratzer B; Tomosel E; Kutschera M; Tobudic S; Pickl WF; Kundi M; Stockinger H; Novacek G; Reinisch W; Zielinski C; Wiedermann U
    Front Immunol; 2022; 13():889138. PubMed ID: 35634285
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Correlation between BNT162b2 mRNA Covid-19 vaccine-associated hypermetabolic lymphadenopathy and humoral immunity in patients with hematologic malignancy.
    Cohen D; Hazut Krauthammer S; Cohen YC; Perry C; Avivi I; Herishanu Y; Even-Sapir E
    Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3540-3549. PubMed ID: 33966088
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of BNT162b2 vaccination in patients with solid cancer receiving anticancer therapy - a single centre prospective study.
    Shmueli ES; Itay A; Margalit O; Berger R; Halperin S; Jurkowicz M; Levin EG; Levy I; Olmer L; Regev-Yochay G; Lustig Y; Rahav G
    Eur J Cancer; 2021 Nov; 157():124-131. PubMed ID: 34508994
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2).
    Favresse J; Bayart JL; Mullier F; Dogné JM; Closset M; Douxfils J
    Clin Microbiol Infect; 2021 Sep; 27(9):1351.e5-1351.e7. PubMed ID: 33975007
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech).
    Korth J; Jahn M; Dorsch O; Anastasiou OE; Sorge-Hädicke B; Eisenberger U; Gäckler A; Dittmer U; Witzke O; Wilde B; Dolff S; Kribben A
    Viruses; 2021 Apr; 13(5):. PubMed ID: 33923063
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The ROMANOV study found impaired humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in virus-unexposed patients receiving maintenance hemodialysis.
    Espi M; Charmetant X; Barba T; Koppe L; Pelletier C; Kalbacher E; Chalencon E; Mathias V; Ovize A; Cart-Tanneur E; Bouz C; Pellegrina L; Morelon E; Fouque D; Juillard L; Thaunat O
    Kidney Int; 2021 Oct; 100(4):928-936. PubMed ID: 34284044
    [TBL] [Abstract][Full Text] [Related]  

  • 52. SARS-CoV-2 vaccine humoral response in adults with Down syndrome.
    Sali M; Carfì A; Di Paola A; Pereyra Boza M; Zampino G; Sanguinetti M; Landi F; Onder G
    Clin Microbiol Infect; 2022 Aug; 28(8):1155.e1-1155.e4. PubMed ID: 35461998
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Strong T-cell activation in response to COVID-19 vaccination in multiple sclerosis patients receiving B-cell depleting therapies.
    Alfonso-Dunn R; Lin J; Kirschner V; Lei J; Feuer G; Malin M; Liu J; Roche M; Sadiq SA
    Front Immunol; 2022; 13():926318. PubMed ID: 35990701
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Immunogenicity and safety of a booster vaccination with an inactivated severe acute respiratory syndrome coronavirus 2 vaccine in adults aged 18 to 59 years].
    Pan HX; Huang BY; Deng Y; Chu K; Hu JL; Zhu DD; Wu JL; Zhang L; Wang M; Huang WJ; Tan WJ
    Zhonghua Yi Xue Za Zhi; 2022 Jan; 102(4):279-285. PubMed ID: 35073677
    [No Abstract]   [Full Text] [Related]  

  • 55. The effectiveness of the first dose COVID-19 booster vs. full vaccination to prevent SARS-CoV-2 infection and severe COVID-19 clinical event: a meta-analysis and systematic review of longitudinal studies.
    Xu J; Lan X; Zhang L; Zhang X; Zhang J; Song M; Liu J
    Front Public Health; 2023; 11():1165611. PubMed ID: 37325336
    [TBL] [Abstract][Full Text] [Related]  

  • 56. RBD- specific Th1 responses are associated with vaccine-induced protection against SARS-CoV-2 infection in patients with hematological malignancies.
    Bigenwald C; Haddad Y; Thelemaque C; Carrier A; Birebent R; Ly P; Flament C; Lahmar I; de Sousa E; Maeurer M; Miyara M; Assi T; Castilla-Llorente C; Willekens C; Fayemi C; Lazarovici J; Marabelle A; Derosa L; Ribrag V; Zitvogel L
    Oncoimmunology; 2023; 12(1):2163785. PubMed ID: 36632566
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Humoral response to mRNA-based COVID-19 vaccine and booster effect of a third dose in patients with mature T cell and NK-cell neoplasms.
    Kobayashi M; Mori A; Onozawa M; Tsukamoto S; Senjo H; Ishio T; Yokoyama E; Kanaya M; Izumiyama K; Saito M; Muraki H; Morioka M; Teshima T; Kondo T
    Ann Hematol; 2023 Apr; 102(4):819-827. PubMed ID: 36862167
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunogenicity of the third and fourth BNT162b2 mRNA COVID-19 boosters and factors associated with immune response in patients with SLE and rheumatoid arthritis.
    Assawasaksakul T; Sathitratanacheewin S; Vichaiwattana P; Wanlapakorn N; Poovorawan Y; Avihingsanon Y; Assawasaksakul N; Kittanamongkolchai W
    Lupus Sci Med; 2022 Jul; 9(1):. PubMed ID: 35902168
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dynamic Evolution of Humoral and T-Cell Specific Immune Response to COVID-19 mRNA Vaccine in Patients with Multiple Sclerosis Followed until the Booster Dose.
    Ruggieri S; Aiello A; Tortorella C; Navarra A; Vanini V; Meschi S; Lapa D; Haggiag S; Prosperini L; Cuzzi G; Salmi A; Quartuccio ME; Altera AMG; Garbuglia AR; Ascoli Bartoli T; Galgani S; Notari S; Agrati C; Puro V; Nicastri E; Gasperini C; Goletti D
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239872
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Analysis of Rituximab Use, Time Between Rituximab and SARS-CoV-2 Vaccination, and COVID-19 Hospitalization or Death in Patients With Multiple Sclerosis.
    Smith JB; Gonzales EG; Li BH; Langer-Gould A
    JAMA Netw Open; 2022 Dec; 5(12):e2248664. PubMed ID: 36576740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 55.